| Date | Title | Description |
| 14.03.2025 | Фармацевтические компании Mallinckrodt и Endo объединятся за почти $7 млрд | Акционеры Endo получат $80 млн наличными и будут владеть 49,9% объединенной компании, в то время как акционеры Mallinckrodt будут владеть оставшейся частью, а стоимость предприятия составит $6,7 млрд, сообщили компании в четверг.
Новая комп... |
| 12.09.2024 | Fourth Annual Prevent Blindness Inflammatory Eye Disease (IED) Awareness Week Declared as Sept. 16 - 22, 2024 | Prevent Blindness declares Sept. 16 – 22, 2024 as its Fourth Annual Inflammatory Eye Disease (IED) Awareness Week, seeking to educate patients on the various types of IEDs and treatment options.
Prevent Blindness Offers Free Resources to He... |
| 12.09.2024 | Qualifyze: Life Sciences Supplier Risk Management Company Raises $54 Million (Series B) | Qualifyze, a supplier risk management company in the Life Sciences industry, announced $54 million in Series B funding from Insight Partners. Existing investors HV Capital, HarbourVest Partners, H14, and Cherry Ventures also participated.
W... |
| 10.09.2024 | Qualifyze Raises $54M in Series B Funding | Qualifyze, a Frankfurt, Germany-based company which specializes in supply chain risk management in the Life Sciences industry, raised $54M in Series B funding.
The round was led by Insight Partners, with participation from existing investor... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 20.08.2024 | The Battle for Truth: Navigating the Landscape of Cancer Research and Disinformation | In the realm of cancer research, hope is a beacon. The Society for Immunotherapy of Cancer (SITC) shines that light brightly. Their recent announcement of fellowship recipients is a testament to the commitment to innovation and progress. Wi... |
| 19.08.2024 | Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships | SITC Logo
In its mission to make "cure" a reality for cancer patients everywhere and support the development of early career investigators, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the rec... |
| 09.08.2024 | Mallinckrodt's Strategic Shift: A $925 Million Deal and Financial Resurgence | In a bold move, Mallinckrodt plc has agreed to sell its Therakos business to CVC Capital Partners for $925 million. This transaction marks a significant pivot for the company, which is keen on streamlining its operations and reducing its de... |
| 06.08.2024 | Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance | Achieves Second Quarter Net Sales of $514.3 Million, Reflecting 8.3% Year-Over-Year Growth on a Reported Basis and 8.4% on a Constant Currency Basis
Reports Net Loss of $43.3 Million, Reflecting a 94.2% Year-Over-Year Improvement; Delivers ... |
| 05.08.2024 | Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million | Divestiture Advances Mallinckrodt's Strategic Priorities to Optimize Capital Structure and Focus on Core Areas of Expertise
Mallinckrodt to Use Net Proceeds to Reduce Net Debt by More Than 50%
CVC Brings Resources and Expertise to Further D... |
| 09.05.2024 | Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance | Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2% Year-Over-Year Growth on a Reported and Constant Currency Basis
Reports Net Loss of $65.4 Million, Reflecting a 73.8% Year-Over-Year Improvement; Delivers Adjusted EBITDA ... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 03.05.2024 | Patients on hunt for diabetes, obesity and weight-loss drugs | - |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 10.10.2023 | Mallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1 Billion in Opioid Payments | - |
| 12.05.2023 | API Innovation Center to Solidify U.S. Active Pharmaceutical Ingredient Manufacturing Base Through Partnerships | API Innovation Center Announced Agreement to Accelerate Adoption of Low-Cost Pharmaceutical Manufacturing Technologies to Support U.S. Medicine Production ST. LOUIS, MISSOURI , UNITED STATES , May 12, 2023/EINPresswire.com/ -- The API Innov... |
| 20.09.2022 | Prevent Blindness Declares Second Annual Inflammatory Eye Disease Awareness Week as Sept. 26 – Oct. 2 | Prevent Blindness declares Sept. 26 – Oct. 2, 2022, as the second annual Inflammatory Eye Disease (IED) Awareness Week. “Inflammatory Eye Disease is a term that encompasses a wide variety of diseases and symptoms,” said Jeff Todd, president... |
| 17.06.2022 | Attorney General Tong Announces $230 Million Settlement with Mallinckrodt Over Underpayment of Medicaid Drug Rebates | Press Releases
06/17/2022 Attorney General Tong Announces $230 Million Settlement with Mallinckrodt Over Underpayment of Medicaid Drug Rebates (Hartford, CT) -- Attorney General William Tong today announced a $230 million multistate settlem... |
| 22.02.2022 | Mallinckrodt chalks up CRL to packaging and labeling facility struggles | Mallinckrodt has been handed a complete response letter in connection to its NDA seeking approval for terlipressin, its drug to treat a rare kidney disease.
The CRL comes as the Irish-American pharma scrambled to find a new packaging and la... |
| 12.11.2021 | The National Alliance for Caregiving Releases a New White Paper Analyzing the Existing Impact of Incentives on Caregiver Services | The paper discuses significant components that contribute to systemic setbacks, including specifics around variation in payment models, insurance coverages, health care settings and provider types.
WASHINGTON (PRWEB) November 12, 2021
In a ... |
| 28.10.2021 | Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photoph... | - In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison -
DUBLIN, Ireland and LAKEWOOD, Colo. USA - Octo... |
| 21.09.2021 | Prevent Blindness Declares First-ever Inflammatory Eye Disease Awareness Week as Sept. 27 – Oct. 3 | Prevent Blindness has declared Sept. 27 – Oct. 3, 2021, as "Inflammatory Eye Disease Awareness Week" to educate the public on importance of early detection and treatment to save sight. “As with most eye diseases and conditions, ac... |
| 03.09.2021 | Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien Noteholders | |
| 05.08.2021 | New Guidebook for Caregivers of Children with Rare and/or Serious Illnesses | The Circle of Care Guidebook for Caregivers of Children with Rare and/or Serious Illnesses addresses the ups and downs of caring for a child living with advanced illness and medical complexity, offering new resources, personal stories, and ... |
| 07.07.2021 | Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns | |
| 01.07.2021 | Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary Sarcoidosis | |
| 10.03.2021 | Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans | |
| 04.03.2021 | Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) | |
| 18.02.2021 | Mallinckrodt becomes the latest victim of the FDA's pandemic-related delays as it pushes off application for skin graft | With Covid-19 locking down travel across the world, not even drug safety regulators have been spared from costly delays. For the FDA, whose inspection schedule keeps the trains on time for new marketing approvals, those delay... |
| 12.02.2021 | Mallinckrodt Provides Regulatory Update on StrataGraft® | |
| 01.12.2020 | Slone Partners Places Kevin B. Johnson as Senior Vice President of Regulatory Affairs at Inozyme Pharma | “Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless.
SOUTH RIDING, Va. (PRWEB) December 01, 2020
Sl... |
| 16.11.2020 | Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience | |
| 16.11.2020 | Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with Liver Disease at The Liver Meeting Digital Experience | |
| 14.10.2020 | Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations | |
| 12.10.2020 | Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring | |
| 14.09.2020 | Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1) | |
| 10.09.2019 | Shedding non-core units while loading up on cash, Mallinckrodt bags $250M in CDMO sale | Mallinckrodt may not be spinning off its specialty generics business any time soon, but the UK drugmaker is seizing every chance to shed subsidiaries that don’t belong in the branded drug company it’s keen to consolidate in... |
| 17.07.2019 | Mallinckrodt forced to shutter ALS study testing its controversial Acthar gel | Mallinckrodt, the current maker of Acthar — a drug first developed in the 1950s — said on Tuesday said it was abandoning its quest to market the gel in patients with Lou Gehrig’s disease.
The company was testing the drug in a... |
| 06.06.2019 | Vivek Ramaswamy recruits Eli Lilly R&D vet Salzmann as new CEO; Axovant drops collaboration | → Vivek Ramaswamy has recruited Eli Lilly R&D vet Pete Salzmann to take the helm at one of his new vants. Salzmann is the new CEO at Immunovant, which is working on IMVT-1401, a monoclonal antibody in development for t... |
| 05.06.2019 | Mallinckrodt to pay $15 million to settle marketing probe, but will fight a charity kickback case | Amid a growing number of probes into the pharmaceutical industry, Mallinckrodt (MNK) tentatively agreed to pay $15.4 million to settle charges of illegal marketing by Questcor, a company that it purchased five years ago and was infamous for... |
| 21.05.2019 | Mallinckrodt sues CMS over Medicaid rebates for its pricey Acthar Gel medicine | In an unexpected development, Mallinckrodt (MNK) filed a lawsuit accusing the federal government of illegally resetting a benchmark used for calculating rebates the company must pay to Medicaid for its most important drug, a move that could... |
| 12.12.2018 | Mallinckrodt's woes persist as reformulated opioid painkiller fails to pass FDA muster | The FDA’s reluctance with prescription painkillers at a time the United States is swept by a tsunami of opioid abuse, overdose and addiction was on full display on Wednesday, when the regulator rejected Mallinckrodt’s $MNK... |
| 27.12.2017 | Mallinckrodt To Acquire Sucampo Pharmaceuticals For $1.2B | Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global biopharmaceutical company, today announced that they have entered into an agreement under which Mall... |
| 26.12.2017 | On a deal spree, Mallinckrodt bags Sucampo and two late-stage rare disease drugs for $1.2B | The biotech year is ending with a light bang on the M&A front.
Suffering from a rep based more on exploiting markets than developing new drugs, Mallinckrodt $MNK is beefing up its pipeline of rare disease drugs with the $1.2... |
| 24.07.2017 | Report breaks down how much Congressmen are getting from Pharma PACs | This year, the company left the industry trade group Pharmaceutical Research and Manufacturers of America, or PhRMA, after the group threatened to kick out companies that did not spend enough on research.
Mallinckrodt, however, has been inc... |
| 31.05.2017 | Term Sheet — Wednesday, May 31 | CRYPTO BUBBLE, DIVERSITY, JOBS, BURNOUT
Good morning. Many, many private equity deals this morning, including two notable acquisitions for Vista Equity Partners and a $13.5 billion Blackstone exit that isn’t an IPO. Plus a new health-tech u... |
| 05.04.2017 | Much criticized Mallinckrodt bows out of PhRMA ahead of some tightened restrictions on membership | Mark Tyndall, Mallinckrodt
Just ahead of some new, more muscular rules governing who can be a part of the industry lobbying organization PhRMA, one of its most heavily criticized members is pulling out.
PhRMA confirmed t... |
| 17.02.2017 | Nine months of rheumatoid arthritis suppression with one stem cell dose? | While much larger Phase 3 studies are needed to validate the results, the data offer a tantalizing look at what optimized and targeted regenerative medicines could do as the field moves closer to an approval.
The study involved 48 patients ... |
| 30.01.2017 | Term Sheet — Monday, January 30 | THE WEEKEND
The tech industry has found its backbone, making increasingly bold statements and donations in reaction to President Trump’s order to deny entry to refugees and citizens of predominantly Muslim countries over the weekend. It cul... |
| 25.08.2016 | CapVest-owned IBA Molecular to Acquire Mallinckrodt’s Nuclear Imaging Business for $690M | Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM), for approximately $690 ... |
| 18.08.2016 | Protocols: Mallinckrodt lands a new corporate campus in NJ; Nutrinia bags a $30M round for oral insulin | Following a string of acquisitions, Mallinckrodt is investing $80 million to create a new campus in New Jersey for its development and sales crew. About 400 staffers will move in to the Somerset Financial Center, 1405-14... |
| 17.11.2015 | How a price hike for a drug for infants with epilepsy drove an uproar | This week celebrity blogger Perez Hilton and a handful of more traditional media outlets wrote about a 2,000 percent price hike for a drug used to treat infants with a rare form of epilepsy. Critics derided what they described as “price-gou... |
| - | Report breaks down how much Congressmen are getting from Pharma PACs | Two federal investigations — one examining opioid sales, another about a multiple sclerosis drug whose price had soared to $34,000 a vial — were only part of the troubles Mallinckrodt faced as the year began.
The stock of the drugmaker, who... |
| - | Nine months of rheumatoid arthritis suppression with one stem cell dose? | Dividing mesenchymal stem cells
It’s the kind of the data the field has worked towards for years.
Rheumatoid arthritis (RA) patients given a single intravenous dose of Mesoblast’s novel stem cell therapy were still demonstrating therapeutic... |
